3140 days ago,
303 views
3140 days ago,
303 views
Martin Shkreli, 32, the founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim
A former hedge fund manager turned pharmaceutical businessman has purchased the rights to a 62-year-old dt to $750 bringing the annual cost of treatment for some patients to hundreds of thousands of dollars.
